Related Experiment Video
Updated: Jul 23, 2025

Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Optimal timing of heart transplantation in patients with an implantable left ventricular assist device
Suk Ho Sohn1, Yoonjin Kang1, Ho Young Hwang1
1Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Insights
Left ventricular assist devices (LVADs) offer benefits for heart failure patients awaiting heart transplantation (HTPL). However, LVADs have limitations, and optimal timing for HTPL post-LVAD requires further research.
Area of Science:
- Cardiovascular Surgery
- Heart Failure Management
- Mechanical Circulatory Support
Background:
- Heart transplantation (HTPL) is the gold standard for end-stage heart failure.
- Increasing reliance on left ventricular assist devices (LVADs) as a bridge to HTPL due to donor scarcity.
- Over half of current HTPL recipients utilize durable LVADs.
Purpose of the Study:
- To review the benefits and limitations of LVADs used as a bridge to HTPL.
- To evaluate current literature on the optimal timing for HTPL after LVAD implantation.
Main Methods:
- Narrative review of existing literature.
- Analysis of benefits and shortcomings of LVADs.
- Examination of studies concerning HTPL timing post-LVAD.
Main Results:
- LVADs provide significant advantages for patients awaiting HTPL.
- Limitations of LVADs include loss of pulsatility, thromboembolism, bleeding, and infection.
- Limited studies exist on optimal HTPL timing with third-generation LVADs.
Conclusions:
- LVADs are crucial in managing heart failure patients awaiting transplantation.
- Further research is necessary to establish definitive guidelines for HTPL timing after LVAD implantation, especially with advanced devices.
Abstract:
Heart transplantation (HTPL) has been established as the gold-standard surgical treatment for end-stage heart failure. However, the use of a left ventricular assist device (LVAD) as a bridge to HTPL has been increasing due to the limited availability of HTPL donors. Currently, more than half of HTPL patients have a durable LVAD. Advances in LVAD technology have provided many benefits for patients on the waiting list for HTPL. Despite their advantages, LVADs also have limitations such as loss of pulsatility, thromboembolism, bleeding, and infection. In this narrative review, the benefits and shortcomings of LVADs as a bridge to HTPL are summarized, and the available literature evaluating the optimal timing of HTPL after LVAD implantation is reviewed. Because only a few studies have been published on this issue in the current era of third-generation LVADs, future studies are needed to draw a definite conclusion.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy

